Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Fifteen of the biotechnology company's products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra. The media giant will take ownership of the ...

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4 ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Amgen reported higher profit and revenue in the second quarter after 15 of the biotechnology company's products saw at least double-digit sales growth. The Thousand Oaks, Calif.-based biotechnology ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...